Article History
Received: 15 December 2019
Accepted: 28 February 2020
First Online: 25 March 2020
Competing interests
: Dr. Mohr has accepted honoraria and consulting fees from Apple Inc., Otsuka America Pharmaceutical Inc., and has an ownership interest in Adaptive Health, Inc. Dr. Hotopf is the principal investigator of the RADAR-CNS consortium—a precompetitive public–private partnership jointly funded by the Innovative Medicines Initiative and European Federation of Pharmaceutical Industries and Associations. As such, he receives research funding and in kind contributions from five pharmaceutical companies—Janssen, Biogen, UCB, Lundbeck, and Merck Sharp & Dohme. Dr. Shilton has no competing interests.